<p>Progyny（纳斯达克代码：PGNY - 获取免费报告）在周四发布的研究报告中被 Zacks Research 从 “持有” 评级上调至 “强烈买入” 评级，Zacks.com 报道。</p>
<ul>
<li>你可能从未听说过的三只最佳股票</li>
</ul>
<p>其他股票分析师最近也对该股票发布了研究报告。Weiss Ratings 在 3 月 27 日的研究报告中重新发布了 Progyny 的 “持有（c）” 评级。华尔街 Zen 在 4 月 18 日的研究报告中将 Progyny 的评级从 “持有” 上调至 “买入”。摩根大通在 1 月 21 日的研究报告中对 Progyny 设定了 35.00 美元的目标价。Truist Financial 在 3 月 2 日的研究报告中将 Progyny 的目标价从 34.00 美元下调至 28.00 美元，并对该公司设定了 “买入” 评级。最后，Jefferies Financial Group 在 3 月 6 日的研究报告中重申了 “买入” 评级，并对 Progyny 的目标价设定为 30.00 美元。一位研究分析师对该股票给予了强烈买入评级，九位分析师给予了买入评级，三位分析师给予了持有评级。根据 MarketBeat 的数据，该股票的平均评级为 “适度买入”，平均目标价为 27.91 美元。</p>
<p><strong>查看我们对 Progyny 的最新分析</strong></p>
<h2>Progyny 股票上涨 23.8%</h2>
<p>PGNY 股票在周四开盘价为 23.72 美元。Progyny 的 12 个月低点为 16.10 美元，12 个月高点为 28.75 美元。该公司的市值为 18.6 亿美元，市盈率为 30.81，市盈增长比率为 1.10，贝塔值为 0.91。该公司的 50 日简单移动平均线为 17.87 美元，200 日简单移动平均线为 21.69 美元。</p>
<p>Progyny（纳斯达克代码：PGNY - 获取免费报告）最后一次公布季度财报是在 5 月 7 日。该公司报告本季度每股收益为 0.29 美元，超出市场共识预期的 0.26 美元，超出幅度为 0.03 美元。该季度的营业收入为 3.285 亿美元，而市场共识预期为 3.2647 亿美元。Progyny 的股本回报率为 12.76%，净利润率为 5.23%。Progyny 本季度的收入同比下降了 26.4%。在去年同期，该公司每股收益为 0.17 美元。Progyny 已将其 2026 财年的指导目标设定为 1.980-2.09 美元每股，并将其 2026 年第二季度的指导目标设定为 0.500-0.53 美元。作为一个整体，股票研究分析师预计 Progyny 在当前财年将发布 1.12 美元的每股收益。</p>
<h2>内部活动</h2>
<p>在其他新闻中，执行副总裁 Allison Swartz 在 3 月 3 日的交易中出售了 4,657 股该公司的股票。股票以平均价格 17.40 美元出售，总交易额为 81,031.80 美元。交易完成后，该执行副总裁持有该公司 89,879 股股票，价值约为 1,563,894.60 美元。这笔交易代表了他们持股比例的 4.93% 的减少。该交易已在与证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站获取。在过去的 90 天内，内部人士共出售了 7,455 股公司股票，价值 129,515 美元。公司内部人士目前持有 9.90% 的股票。</p>
<h2>对 Progyny 的对冲基金看法</h2>
<p>大型投资者最近调整了对该公司的持股。凯通国际资产管理有限公司在第四季度购买了 Progyny 的新股份，价值 25,000 美元。Federated Hermes Inc.在第三季度将其在 Progyny 的持股增加了 147.3%。Federated Hermes Inc.现在拥有 1,375 股该公司的股票，价值 30,000 美元，此前在上个季度又购买了 819 股。Hantz Financial Services Inc.在第四季度将其在 Progyny 的持股增加了 79.4%。Hantz Financial Services Inc.现在拥有 1,676 股该公司的股票，价值 43,000 美元，此前在上个季度又购买了 742 股。Versant Capital Management Inc 在第三季度将其在 Progyny 的持股增加了 61.8%。Versant Capital Management Inc 现在拥有 2,340 股该公司的股票，价值 50,000 美元，此前在上个季度又购买了 894 股。最后，Covestor Ltd 在第三季度将其在 Progyny 的持股增加了 164.9%。Covestor Ltd 现在拥有 2,609 股该公司的股票，价值 56,000 美元，此前在上个季度又购买了 1,624 股。机构投资者持有该公司 94.93% 的股票。</p>
<h2>Progyny 的关键新闻</h2>
<p>以下是本周影响 Progyny 的关键新闻：</p>
<ul>
<li>积极情绪：Progyny 超出第一季度预期，报告调整后每股收益为 0.50 美元，而预期为 0.44 美元，营业收入为 3.285 亿美元，而预期为 3.265 亿美元，推动股票上涨。Progyny, Inc.宣布 2026 年第一季度业绩</li>
<li>积极情绪：该公司上调了 2026 年第二季度和全年指导，第二季度每股收益预期为 0.50 至 0.53 美元，2026 财年每股收益指导为 1.98 至 2.09 美元，均高于华尔街预期，增强了对未来盈利能力的信心。电话会议和财报材料</li>
<li>积极情绪：管理层表示，早期销售季节活动和会员参与度强劲，并强调持续的股票回购，自 11 月以来回购了 880 万股，给投资者提供了另一个支持信号。Progyny, Inc.宣布 2026 年第一季度业绩</li>
<li>中性情绪：收入同比仍下降 26.4%，因此尽管本季度超出预期，投资者可能仍会关注增长能否在近期下降后稳定。Progyny：第一季度财报快照</li>
<li>中性情绪：一些评论指出对平稳收入指导的担忧，如果投资者希望未来有更清晰的收入加速，这可能会抑制乐观反应。Progyny（PGNY）的牛市前景可能因平稳的 2026 年第一季度收入指导担忧而改变</li>
</ul>
<h2>Progyny 公司简介</h2>
<p>（获取免费报告）</p>
<p>Progyny, Inc 是一家总部位于纽约的生育福利管理公司，与雇主和健康计划合作，设计和管理全面的家庭建设项目。该公司的数字健康平台整合了临床专业知识、患者支持工具和数据分析，帮助会员导航生育治疗，从体外受精（IVF）和冻卵到代孕和收养。通过关注基于结果的护理，Progyny 旨在提高成功率，同时控制客户的成本。</p>
<p>Progyny 产品的核心是其专有的 Smart Cycle®福利，将临床、情感和后勤支持整合为一个单一的套餐。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UEdOWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UEdOWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Progyny 吗？</h2>
<p>在考虑 Progyny 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Progyny 并不在名单上。</p>
<p>虽然 Progyny 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

PGNY

<p>Zacks Research 将 Progyny (NASDAQ: PGNY) 的评级从 “持有” 上调至 “强烈买入”。其他分析师也给出了混合评级，其中包括一项强烈买入、九项买入和三项持有。该股票上涨了 23.8%，开盘价为 23.72 美元，市值为 18.6 亿美元。Progyny 报告第一季度每股收益为 0.29 美元，超出预期，但收入同比下降了 26.4%。机构投资者持有该股票的 94.93%，最近的内部交易包括执行副总裁 Allison Swartz 的股票出售</p>

<p>Progyny (NASDAQ:PGNY - Get Free Report) was upgraded by Zacks Research from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note issued on Thursday,Zacks.com reports.</p>
<div class="lb-trans"><p>Progyny（纳斯达克代码：PGNY - 获取免费报告）在周四发布的研究报告中被 Zacks Research 从 “持有” 评级上调至 “强烈买入” 评级，Zacks.com 报道。</p>
</div><ul>
<li>3 Best Stocks to Buy That You’ve Probably Never Heard Of</li>
</ul>
<div class="lb-trans"><ul>
<li>你可能从未听说过的三只最佳股票</li>
</ul>
</div><p>Other equities analysts also recently issued research reports about the stock. Weiss Ratings reissued a &#34;hold (c)&#34; rating on shares of Progyny in a research note on Friday, March 27th. Wall Street Zen raised shares of Progyny from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Saturday, April 18th. JPMorgan Chase &amp; Co. set a $35.00 price objective on shares of Progyny in a research note on Wednesday, January 21st. Truist Financial dropped their price objective on shares of Progyny from $34.00 to $28.00 and set a &#34;buy&#34; rating for the company in a research note on Monday, March 2nd. Finally, Jefferies Financial Group reiterated a &#34;buy&#34; rating and issued a $30.00 target price on shares of Progyny in a research report on Friday, March 6th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of &#34;Moderate Buy&#34; and an average price target of $27.91.</p>
<div class="lb-trans"><p>其他股票分析师最近也对该股票发布了研究报告。Weiss Ratings 在 3 月 27 日的研究报告中重新发布了 Progyny 的 “持有（c）” 评级。华尔街 Zen 在 4 月 18 日的研究报告中将 Progyny 的评级从 “持有” 上调至 “买入”。摩根大通在 1 月 21 日的研究报告中对 Progyny 设定了 35.00 美元的目标价。Truist Financial 在 3 月 2 日的研究报告中将 Progyny 的目标价从 34.00 美元下调至 28.00 美元，并对该公司设定了 “买入” 评级。最后，Jefferies Financial Group 在 3 月 6 日的研究报告中重申了 “买入” 评级，并对 Progyny 的目标价设定为 30.00 美元。一位研究分析师对该股票给予了强烈买入评级，九位分析师给予了买入评级，三位分析师给予了持有评级。根据 MarketBeat 的数据，该股票的平均评级为 “适度买入”，平均目标价为 27.91 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on Progyny</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Progyny 的最新分析</strong></p>
</div><h2>Progyny Stock Up 23.8%</h2>
<div class="lb-trans"><h2>Progyny 股票上涨 23.8%</h2>
</div><p>Shares of PGNY stock opened at $23.72 on Thursday. Progyny has a twelve month low of $16.10 and a twelve month high of $28.75. The company has a market cap of $1.86 billion, a P/E ratio of 30.81, a P/E/G ratio of 1.10 and a beta of 0.91. The business has a fifty day simple moving average of $17.87 and a 200 day simple moving average of $21.69.</p>
<div class="lb-trans"><p>PGNY 股票在周四开盘价为 23.72 美元。Progyny 的 12 个月低点为 16.10 美元，12 个月高点为 28.75 美元。该公司的市值为 18.6 亿美元，市盈率为 30.81，市盈增长比率为 1.10，贝塔值为 0.91。该公司的 50 日简单移动平均线为 17.87 美元，200 日简单移动平均线为 21.69 美元。</p>
</div><p>Progyny (NASDAQ:PGNY - Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.26 by $0.03. The business had revenue of $328.50 million during the quarter, compared to the consensus estimate of $326.47 million. Progyny had a return on equity of 12.76% and a net margin of 5.23%.Progyny's revenue for the quarter was down 26.4% on a year-over-year basis. During the same period in the prior year, the company earned $0.17 EPS. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. As a group, equities research analysts anticipate that Progyny will post 1.12 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Progyny（纳斯达克代码：PGNY - 获取免费报告）最后一次公布季度财报是在 5 月 7 日。该公司报告本季度每股收益为 0.29 美元，超出市场共识预期的 0.26 美元，超出幅度为 0.03 美元。该季度的营业收入为 3.285 亿美元，而市场共识预期为 3.2647 亿美元。Progyny 的股本回报率为 12.76%，净利润率为 5.23%。Progyny 本季度的收入同比下降了 26.4%。在去年同期，该公司每股收益为 0.17 美元。Progyny 已将其 2026 财年的指导目标设定为 1.980-2.09 美元每股，并将其 2026 年第二季度的指导目标设定为 0.500-0.53 美元。作为一个整体，股票研究分析师预计 Progyny 在当前财年将发布 1.12 美元的每股收益。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In other news, EVP Allison Swartz sold 4,657 shares of the firm's stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $17.40, for a total transaction of $81,031.80. Following the completion of the transaction, the executive vice president owned 89,879 shares of the company's stock, valued at approximately $1,563,894.60. This trade represents a 4.93% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 7,455 shares of company stock worth $129,515 over the last ninety days. 9.90% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他新闻中，执行副总裁 Allison Swartz 在 3 月 3 日的交易中出售了 4,657 股该公司的股票。股票以平均价格 17.40 美元出售，总交易额为 81,031.80 美元。交易完成后，该执行副总裁持有该公司 89,879 股股票，价值约为 1,563,894.60 美元。这笔交易代表了他们持股比例的 4.93% 的减少。该交易已在与证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站获取。在过去的 90 天内，内部人士共出售了 7,455 股公司股票，价值 129,515 美元。公司内部人士目前持有 9.90% 的股票。</p>
</div><h2>Hedge Funds Weigh In On Progyny</h2>
<div class="lb-trans"><h2>对 Progyny 的对冲基金看法</h2>
</div><p>Large investors have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd bought a new position in shares of Progyny during the fourth quarter valued at $25,000. Federated Hermes Inc. raised its stake in shares of Progyny by 147.3% during the third quarter. Federated Hermes Inc. now owns 1,375 shares of the company's stock valued at $30,000 after acquiring an additional 819 shares during the last quarter. Hantz Financial Services Inc. raised its stake in shares of Progyny by 79.4% during the fourth quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company's stock valued at $43,000 after acquiring an additional 742 shares during the last quarter. Versant Capital Management Inc raised its position in shares of Progyny by 61.8% during the third quarter. Versant Capital Management Inc now owns 2,340 shares of the company's stock worth $50,000 after acquiring an additional 894 shares during the last quarter. Finally, Covestor Ltd raised its position in shares of Progyny by 164.9% during the third quarter. Covestor Ltd now owns 2,609 shares of the company's stock worth $56,000 after acquiring an additional 1,624 shares during the last quarter. Institutional investors own 94.93% of the company's stock.</p>
<div class="lb-trans"><p>大型投资者最近调整了对该公司的持股。凯通国际资产管理有限公司在第四季度购买了 Progyny 的新股份，价值 25,000 美元。Federated Hermes Inc.在第三季度将其在 Progyny 的持股增加了 147.3%。Federated Hermes Inc.现在拥有 1,375 股该公司的股票，价值 30,000 美元，此前在上个季度又购买了 819 股。Hantz Financial Services Inc.在第四季度将其在 Progyny 的持股增加了 79.4%。Hantz Financial Services Inc.现在拥有 1,676 股该公司的股票，价值 43,000 美元，此前在上个季度又购买了 742 股。Versant Capital Management Inc 在第三季度将其在 Progyny 的持股增加了 61.8%。Versant Capital Management Inc 现在拥有 2,340 股该公司的股票，价值 50,000 美元，此前在上个季度又购买了 894 股。最后，Covestor Ltd 在第三季度将其在 Progyny 的持股增加了 164.9%。Covestor Ltd 现在拥有 2,609 股该公司的股票，价值 56,000 美元，此前在上个季度又购买了 1,624 股。机构投资者持有该公司 94.93% 的股票。</p>
</div><h2>Key Progyny News</h2>
<div class="lb-trans"><h2>Progyny 的关键新闻</h2>
</div><p>Here are the key news stories impacting Progyny this week:</p>
<div class="lb-trans"><p>以下是本周影响 Progyny 的关键新闻：</p>
</div><ul>
<li>Positive Sentiment: Progyny beat Q1 estimates, reporting $0.50 adjusted EPS versus $0.44 expected and revenue of $328.5 million versus $326.5 million forecast, helping reinforce the stock’s move higher. Progyny, Inc. Announces First Quarter 2026 Results</li>
<li>Positive Sentiment: The company raised second-quarter and full-year 2026 guidance, with Q2 EPS outlook of $0.50 to $0.53 and FY2026 EPS guidance of $1.98 to $2.09, both above Wall Street estimates, which supports confidence in future earnings power. Conference call and earnings materials</li>
<li>Positive Sentiment: Management said early selling-season activity and member engagement were strong, and the company highlighted continued share repurchases, with 8.8 million shares bought back since November, adding another supportive signal for investors. Progyny, Inc. Announces First Quarter 2026 Results</li>
<li>Neutral Sentiment: Revenue was still down 26.4% year over year, so while the quarter beat expectations, investors may remain focused on whether growth can stabilize after the recent decline. Progyny: Q1 Earnings Snapshot</li>
<li>Neutral Sentiment: Some commentary noted concern around flat revenue guidance, which could temper the bullish reaction if investors want clearer top-line acceleration going forward. The Bull Case For Progyny (PGNY) Could Change Following Flat Q1 2026 Revenue Guidance Concerns</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：Progyny 超出第一季度预期，报告调整后每股收益为 0.50 美元，而预期为 0.44 美元，营业收入为 3.285 亿美元，而预期为 3.265 亿美元，推动股票上涨。Progyny, Inc.宣布 2026 年第一季度业绩</li>
<li>积极情绪：该公司上调了 2026 年第二季度和全年指导，第二季度每股收益预期为 0.50 至 0.53 美元，2026 财年每股收益指导为 1.98 至 2.09 美元，均高于华尔街预期，增强了对未来盈利能力的信心。电话会议和财报材料</li>
<li>积极情绪：管理层表示，早期销售季节活动和会员参与度强劲，并强调持续的股票回购，自 11 月以来回购了 880 万股，给投资者提供了另一个支持信号。Progyny, Inc.宣布 2026 年第一季度业绩</li>
<li>中性情绪：收入同比仍下降 26.4%，因此尽管本季度超出预期，投资者可能仍会关注增长能否在近期下降后稳定。Progyny：第一季度财报快照</li>
<li>中性情绪：一些评论指出对平稳收入指导的担忧，如果投资者希望未来有更清晰的收入加速，这可能会抑制乐观反应。Progyny（PGNY）的牛市前景可能因平稳的 2026 年第一季度收入指导担忧而改变</li>
</ul>
</div><h2>Progyny Company Profile</h2>
<div class="lb-trans"><h2>Progyny 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company's digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.</p>
<div class="lb-trans"><p>Progyny, Inc 是一家总部位于纽约的生育福利管理公司，与雇主和健康计划合作，设计和管理全面的家庭建设项目。该公司的数字健康平台整合了临床专业知识、患者支持工具和数据分析，帮助会员导航生育治疗，从体外受精（IVF）和冻卵到代孕和收养。通过关注基于结果的护理，Progyny 旨在提高成功率，同时控制客户的成本。</p>
</div><p>The core of Progyny's offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.</p>
<div class="lb-trans"><p>Progyny 产品的核心是其专有的 Smart Cycle®福利，将临床、情感和后勤支持整合为一个单一的套餐。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Progyny</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UEdOWQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=PGNY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Progyny Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Progyny 吗？</h2>
</div><p>Before you consider Progyny, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Progyny 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Progyny wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Progyny 并不在名单上。</p>
</div><p>While Progyny currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Progyny 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Progyny (NASDAQ:PGNY) Raised to Strong-Buy at Zacks Research

Market Beat

Progyny

摩根大通

Truist Financial

Jefferies Financial

财通证券

Federated Hermes

Versant Media

科思创

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

Versant Media Group - WI

Progyny（纳斯达克股票代码：PGNY）在 Zacks Research 被上调至强力买入评级